A safe self-administered rapid-acting anti-infective
Developing a broad-use antiviral in an increasingly connected world.
In this NSRI IRAD project, funded in August 2021, a research team of technicians, graduate students and undergraduate students is developing an agent that can be administered either prior to or following viral exposure to prevent illnesses such as COVID-19. This particular anti-infective therapy is distinct because it has the potential to be self-administered as a nasal spray.
- Principal Investigator: Paul Davis, NSRI fellow and Associate Professor of Biology at the University of Nebraska at Omaha
Milestones (as of April 2022)
- Safety established in animal models
- Scale-up synthesis for testing in models
- Early anti-viral responses show promising results
The team will conduct research to understand the safety and efficacy of the therapy in treating coronavirus infection.